AstraZeneca and Eli Lilly announce Alzheimer's clinical trial to continue to Phase III
Potential treatment for early Alzheimer's disease to continue without modification to Phase III. Read More »
Potential treatment for early Alzheimer's disease to continue without modification to Phase III. Read More »
The Japanese Ministry of Health, Labor and Welfare (MHLW) today approved AstraZeneca's Tagrisso (osimertinib, AZD9291). Read More »
AstraZeneca today announced the results from the SOCRATES trial that examined the effectiveness of Brilinta/Brilique (ticagrelor) 90 mg tablets meant to be taken twice a day compared to aspirin100 mg once per day in patients suffering from acute ischemic stroke or transient ischemic attack (TIA). Read More »
Incyte Corp. has announced that it will be presenting 10 abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2016 that will feature data from its emerging development portfolio. Read More »
AstraZeneca and MedImmune have announced that the U.S. Food and Drug Administration (FDA) has granted MEDI-551, an anti-CD19 monoclonal antibody, Orphan Drug Designation. Read More »
AstraZeneca has announced it has completed an agreement that will transfer the rights of Moventig (naloxegol) to Kyowa Hakko Kirin subsidiary, ProStrakan Group. Read More »
AstraZeneca announced this week that it has agreed to the terms of a licensing agreement with China Medical System Holdings Ltd. (CMS) that will give CMS commercialization rights for Plendil (felodipine) in China. Read More »
AstraZeneca and its research and development subsidiary, MedImmune, announced this week that the United States Food and Drug Administration (FDA) has granted durvalumab (MEDI4736) Breakthrough Therapy designation (BTD). Read More »
AstraZeneca announced this week that it, along with its worldwide biologics research and development subsidiary, MedImmune, have entered into an agreement to partner with the University of Michigan and Eli Lilly to develop new therapeutic drugs to treat chronic kidney disease (CKD). Read More »
AstraZeneca announced last week that TAGRISSO has been granted conditional marketing authorization by the European Commission (EC). Read More »
AstraZeneca announced this week that its product Lynparza has been granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA). Read More »
AstraZeneca has joined with GlaxoSmithKline and Johnson & Johnson to collaborate with three world-class universities to start the Apollo Therapeutics Fund. Read More »
The Food and Drug Administration (FDA) approved AstraZeneca's drug Zurampic Dec. 22 as a combination treatment for gout. Read More »
AstraZeneca said Thursday it has completed its agreement to purchase ZS Pharma. Read More »
British drug maker AstraZeneca has enlisted the help of Voluntis to develop a companion mobile app for women with ovarian cancer who are undergoing a combination therapy. Read More »
AstraZeneca entered into three partnerships Nov. 20 aimed at expanding technology capabilities at its new research facility on the Cambridge Biomedical Campus in England. Read More »
Biopharmaceutical company AstraZeneca recently agreed to sell the U.S. rights to its Crohn's disease drug Entocort to Perrigo Company for $380 million. Read More »
Positive data has been received from the Phase II trial for anifrolumab, according to an announcement from MedImmune, which is the development and research portion of AstraZeneca. Read More »
ZS Pharma is set to be acquired by AstraZeneca, according to announcement today from AstraSeneca. Read More »
AstraZeneca has entered into a deal to acquire ZS Pharma for $2.7 billion, giving AstraZeneca access to ZS Pharma's treatments for hyperkalemia. Read More »